journal article·2024-06Open access

VLDL and LDL Subfractions Enhance the Risk Stratification of Individuals Who Underwent Epstein–Barr Virus‐Based Screening for Nasopharyngeal Carcinoma: A Multicenter Cohort Study

Zhenhua Zhou, Tingxi Tang, Nan Li, Qiaocong Zheng, Ting Xiao, Yunming Tian, Jianda Sun, Longshan Zhang, Xiaoqing Wang, Yingqiao Wang, Feng Ye, Zekai Chen, Hanbin Zhang, Xiuting Zheng, Zhen Cai, Laiyu Liu, Jian Guan

Advanced Science· Volume 11· Issue 22

Abstract

Abstract Serological tests for Epstein–Barr virus (EBV) antibodies have been widely conducted for the screening of nasopharyngeal carcinoma (NPC) in endemic areas. Further risk stratification of NPC can be achieved through plasma lipoprotein and metabolic profiles. A total of 297 NPC patients and 149 EBV‐positive participants are enrolled from the NCT03919552 and NCT05682703 cohorts for plasma nuclear magnetic resonance (NMR) metabolomic analysis. Small, dense very low density lipoprotein particles (VLDL‐5) and large, buoyant low density lipoprotein particles (LDL‐1) are found to be closely associated with nasopharyngeal carcinogenesis. Herein, an NMR‐based risk score (NRS), which combines lipoprotein subfractions and metabolic biomarkers relevant to NPC, is developed and well validated within a multicenter cohort. Combining the median cutoff value of the NRS (N50) with that of the serological test for EBV antibodies, the risk stratification model achieves a satisfactory performance in which the area under the curve (AUC) is 0.841 (95% confidence interval: 0.811‐0.871), and the positive predictive value (PPV) reaches 70.08% in the combined cohort. These findings not only suggest that VLDL‐5 and LDL‐1 particles can serve as novel risk factors for NPC but also indicate that the NRS has significant potential in personalized risk prediction for NPC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer-related molecular mechanisms research · RNA modifications and cancer · Viral-associated cancers and disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Radiation Oncology Nanfang Hospital Southern Medical University Guangzhou Guangdong China

Chronic Airways Diseases Laboratory Department of Respiratory and Critical Care Medicine Nanfang Hospital Southern Medical University Guangzhou Guangdong China

Department of Radiation Oncology Yangjiang People's Hospital Yangjiang Guangdong China

Department of Radiation Oncology Huizhou People's Hospital Huizhou Guangdong China

Department of Radiation Oncology Meizhou People's Hospital Meizhou Guangdong China

Department of Laboratory Medicine Nanfang Hospital Southern Medical University Guangzhou Guangdong China

Guangdong Province Key Laboratory of Molecular Tumor Pathology Guangzhou Guangdong China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Guangdong Province · China Postdoctoral Science Foundation

References (38)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.5732/cjc.010.1037710.5732/cjc.010.10377 ↗
3. 10.1016/S0140-6736(19)30956-010.1016/S0140-6736(19)30956-0 ↗
4. 10.1098/rstb.2016.027010.1098/rstb.2016.0270 ↗
5. 10.1002/rmv.175810.1002/rmv.1758 ↗
6. 10.1093/aje/kws40410.1093/aje/kws404 ↗
7. 10.1093/annonc/mdz23110.1093/annonc/mdz231 ↗
8. 10.1038/s41467-021-25402-z10.1038/s41467-021-25402-z ↗
9. 10.1002/ijc.2638010.1002/ijc.26380 ↗
10. 10.1158/2159-8290.CD-21-105910.1158/2159-8290.CD-21-1059 ↗
11. 10.7150/thno.8292010.7150/thno.82920 ↗
12. 10.1038/s41568-021-00378-610.1038/s41568-021-00378-6 ↗
13. 10.1016/j.clinbiochem.2011.03.02510.1016/j.clinbiochem.2011.03.025 ↗
14. 10.1039/C4RA09860A10.1039/C4RA09860A ↗
15. 10.1136/gut.2010.22501110.1136/gut.2010.225011 ↗
16. 10.3389/fcell.2023.118798910.3389/fcell.2023.1187989 ↗
17. 10.3389/fendo.2023.113415410.3389/fendo.2023.1134154 ↗
18. 10.18632/oncotarget.716010.18632/oncotarget.7160 ↗
19. 10.1016/j.cmet.2015.12.00610.1016/j.cmet.2015.12.006 ↗
20. 10.3322/caac.2167010.3322/caac.21670 ↗
21. 10.1186/s13046-019-1309-610.1186/s13046-019-1309-6 ↗
22. 10.1186/s12935-022-02739-z10.1186/s12935-022-02739-z ↗
23. 10.1016/j.cca.2010.08.03810.1016/j.cca.2010.08.038 ↗
24. 10.1016/j.canlet.2016.11.03310.1016/j.canlet.2016.11.033 ↗
25. 10.1186/1471-2407-10-60110.1186/1471-2407-10-601 ↗
26. Zhang T. · Zhonghua Yi Xue Za Zhi · 2016 · 96 · 2545
27. 10.1158/1055-9965.EPI-21-044310.1158/1055-9965.EPI-21-0443 ↗
28. 10.3390/cancers1317428110.3390/cancers13174281 ↗
29. 10.1186/s12885-018-4568-210.1186/s12885-018-4568-2 ↗
30. 10.1038/s41392-022-01151-310.1038/s41392-022-01151-3 ↗
31. 10.1007/s12272-023-01431-810.1007/s12272-023-01431-8 ↗
32. 10.1007/s00784-015-1699-610.1007/s00784-015-1699-6 ↗
33. Walenta S. · Cancer Res. · 2000 · 60 · 916
34. 10.3233/CBM-15051410.3233/CBM-150514 ↗
35. 10.1155/2018/180408610.1155/2018/1804086 ↗
36. 10.3389/fimmu.2022.87619510.3389/fimmu.2022.876195 ↗
37. 10.1056/NEJMoa170171710.1056/NEJMoa1701717 ↗
38. 10.1093/jnci/djad01210.1093/jnci/djad012 ↗